183 related articles for article (PubMed ID: 12848397)
1. HTA responses and the classic HTA report.
Milne R; Clegg A; Stevens A
J Public Health Med; 2003 Jun; 25(2):102-6. PubMed ID: 12848397
[TBL] [Abstract][Full Text] [Related]
2. Health technology assessment.
Hailey D
Singapore Med J; 2006 Mar; 47(3):187-92; quiz 193. PubMed ID: 16518551
[TBL] [Abstract][Full Text] [Related]
3. HTA - Algorithm or Process? Comment on "Expanded HTA: Enhancing Fairness and Legitimacy".
Culyer AJ
Int J Health Policy Manag; 2016 Aug; 5(8):501-505. PubMed ID: 27694664
[TBL] [Abstract][Full Text] [Related]
4. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
5. Health technology assessment of biosimilars worldwide: a scoping review.
Ascef BO; Lopes ACF; de Soárez PC
Health Res Policy Syst; 2020 Aug; 18(1):95. PubMed ID: 32843051
[TBL] [Abstract][Full Text] [Related]
6. Health technology assessment: history and demand.
Stevens A; Milne R; Burls A
J Public Health Med; 2003 Jun; 25(2):98-101. PubMed ID: 12848396
[TBL] [Abstract][Full Text] [Related]
7. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports.
Taylor RS; Elston J
Health Technol Assess; 2009 Jan; 13(8):iii, ix-xi, 1-50. PubMed ID: 19203465
[TBL] [Abstract][Full Text] [Related]
8. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
9. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
[TBL] [Abstract][Full Text] [Related]
10. [Health economics and HTA].
Kulp W; Greiner W
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):257-63. PubMed ID: 16465516
[TBL] [Abstract][Full Text] [Related]
11. Differences between systematic reviews and health technology assessments: a trade-off between the ideals of scientific rigor and the realities of policy making.
Rotstein D; Laupacis A
Int J Technol Assess Health Care; 2004; 20(2):177-83. PubMed ID: 15209177
[TBL] [Abstract][Full Text] [Related]
12. Key principles for the improved conduct of health technology assessments for resource allocation decisions.
Drummond MF; Schwartz JS; Jönsson B; Luce BR; Neumann PJ; Siebert U; Sullivan SD
Int J Technol Assess Health Care; 2008; 24(3):244-58; discussion 362-8. PubMed ID: 18601792
[TBL] [Abstract][Full Text] [Related]
13. Health technology assessment: research trends and future priorities in Europe.
Nielsen CP; Funch TM; Kristensen FB
J Health Serv Res Policy; 2011 Jul; 16 Suppl 2():6-15. PubMed ID: 21737525
[TBL] [Abstract][Full Text] [Related]
14. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
Grimm SE; Strong M; Brennan A; Wailoo AJ
Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
[TBL] [Abstract][Full Text] [Related]
15. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
16. Paradigms in operation: explaining pharmaceutical benefit assessment outcomes in England and Germany.
Kieslich K
Health Econ Policy Law; 2020 Jul; 15(3):370-385. PubMed ID: 30975237
[TBL] [Abstract][Full Text] [Related]
17. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
18. Health technology assessment in Australia: a role for clinical registries?
Scott AM
Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
[TBL] [Abstract][Full Text] [Related]
19. Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries.
Visintin E; Tinelli M; Kanavos P
Health Policy; 2019 Feb; 123(2):118-129. PubMed ID: 30227974
[TBL] [Abstract][Full Text] [Related]
20. Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey.
Vokó Z; Cheung KL; Józwiak-Hagymásy J; Wolfenstetter S; Jones T; Muñoz C; Evers SM; Hiligsmann M; de Vries H; Pokhrel S;
Health Res Policy Syst; 2016 May; 14(1):38. PubMed ID: 27230485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
